WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H530380
CAS#: 1135280-28-2 (phosphate)
Description: KN-92 is an inactive analog of the CaM kinase II inhibitor KN 93.
Hodoodo Cat#: H530380
Name: KN-92 phosphate
CAS#: 1135280-28-2 (phosphate)
Chemical Formula: C24H28ClN2O7PS
Exact Mass: 554.10
Molecular Weight: 554.979
Elemental Analysis: C, 51.94; H, 5.09; Cl, 6.39; N, 5.05; O, 20.18; P, 5.58; S, 5.78
Related CAS #: 1431698-47-3 (HCl) 176708-42-2 (free base) 1135280-28-2 (phosphate)
Synonym: KN-92 phosphate; KN-92; KN 92; KN92.
IUPAC/Chemical Name: (E)-N-(2-(((3-(4-chlorophenyl)allyl)(methyl)amino)methyl)phenyl)-4-methoxybenzenesulfonamide phosphate
InChi Key: XRQHWVVDNMJDEQ-IPZCTEOASA-N
InChi Code: InChI=1S/C24H25ClN2O3S.H3O4P/c1-27(17-5-6-19-9-11-21(25)12-10-19)18-20-7-3-4-8-24(20)26-31(28,29)23-15-13-22(30-2)14-16-23;1-5(2,3)4/h3-16,26H,17-18H2,1-2H3;(H3,1,2,3,4)/b6-5+;
SMILES Code: CN(C/C=C/C1=CC=C(Cl)C=C1)CC2=CC=CC=C2NS(=O)(C3=CC=C(OC)C=C3)=O.O=P(O)(O)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 554.98 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Takeuchi M, Yamamoto T. Apoptosis induced by NAD depletion is inhibited by KN-93 in a CaMKII-independent manner. Exp Cell Res. 2015 Jul 1;335(1):62-7. doi: 10.1016/j.yexcr.2015.05.019. PubMed PMID: 26024774.
2: Ke J, Chen F, Zhang C, Xiao X, Tu J, Dai M, Wang X, Chen B, Chen M. Effects of calmodulin-dependent protein kinase II inhibitor, KN-93, on electrophysiological features of rabbit hypertrophic cardiac myocytes. J Huazhong Univ Sci Technolog Med Sci. 2012 Aug;32(4):485-9. doi: 10.1007/s11596-012-0084-9. PubMed PMID: 22886958.
3: Popovic MA, Stojilkovic SS, Gonzalez-Iglesias AE. Effects of isoquinolonesulfonamides on action potential secretion coupling in pituitary cells. Horm Mol Biol Clin Investig. 2010 Jan;1(1):35-42. doi: 10.1515/HMBCI.2010.005. PubMed PMID: 25961970.
4: An P, Zhu JY, Yang Y, Lv P, Tian YH, Chen MK, Luo HS. KN-93, a specific inhibitor of CaMKII inhibits human hepatic stellate cell proliferation in vitro. World J Gastroenterol. 2007 Mar 7;13(9):1445-8. PubMed PMID: 17457979; PubMed Central PMCID: PMC4146932.
5: Ke J, Zhang CT, Ma YX, Liu J, Zhang QY, Liu N, Ruan YF, Lin L. [The effects of calmodulin kinase II inhibitor on ventricular arrhythmias in rabbits with cardiac hypertrophy]. Zhonghua Xin Xue Guan Bing Za Zhi. 2007 Jan;35(1):33-6. Chinese. PubMed PMID: 17386161.
6: Banerjee C, Khatri P, Raman R, Bhatia H, Datta M, Mazumder S. Role of calmodulin-calmodulin kinase II, cAMP/protein kinase A and ERK 1/2 on Aeromonas hydrophila-induced apoptosis of head kidney macrophages. PLoS Pathog. 2014 Apr 24;10(4):e1004018. doi: 10.1371/journal.ppat.1004018. PubMed PMID: 24763432; PubMed Central PMCID: PMC3999153.
7: Ninan I, Jardemark KE, Liang X, Wang RY. Calcium/calmodulin-dependent kinase II is involved in the facilitating effect of clozapine on NMDA- and electrically evoked responses in the medial prefrontal cortical pyramidal cells. Synapse. 2003 Mar 15;47(4):285-94. PubMed PMID: 12539202.
8: Brooks IM, Tavalin SJ. Ca2+/calmodulin-dependent protein kinase II inhibitors disrupt AKAP79-dependent PKC signaling to GluA1 AMPA receptors. J Biol Chem. 2011 Feb 25;286(8):6697-706. doi: 10.1074/jbc.M110.183558. PubMed PMID: 21156788; PubMed Central PMCID: PMC3057809.
9: Lisachev PD, Pustyl'nik VO, Shtark MB. [Regulation of S100B expression during long term potentiation]. Ross Fiziol Zh Im I M Sechenova. 2014 Aug;100(8):953-63. Russian. PubMed PMID: 25682687.
10: Chiluiza D, Krishna S, Schumacher VA, Schlöndorff J. Gain-of-function mutations in transient receptor potential C6 (TRPC6) activate extracellular signal-regulated kinases 1/2 (ERK1/2). J Biol Chem. 2013 Jun 21;288(25):18407-20. doi: 10.1074/jbc.M113.463059. PubMed PMID: 23645677; PubMed Central PMCID: PMC3689983.
11: Groth RD, Lindskog M, Thiagarajan TC, Li L, Tsien RW. Beta Ca2+/CaM-dependent kinase type II triggers upregulation of GluA1 to coordinate adaptation to synaptic inactivity in hippocampal neurons. Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):828-33. doi: 10.1073/pnas.1018022108. PubMed PMID: 21187407; PubMed Central PMCID: PMC3021030.
12: Liu N, Ruan Y, Denegri M, Bachetti T, Li Y, Colombi B, Napolitano C, Coetzee WA, Priori SG. Calmodulin kinase II inhibition prevents arrhythmias in RyR2(R4496C+/-) mice with catecholaminergic polymorphic ventricular tachycardia. J Mol Cell Cardiol. 2011 Jan;50(1):214-22. doi: 10.1016/j.yjmcc.2010.10.001. PubMed PMID: 20937285.
13: Song YH, Cho H, Ryu SY, Yoon JY, Park SH, Noh CI, Lee SH, Ho WK. L-type Ca(2+) channel facilitation mediated by H(2)O(2)-induced activation of CaMKII in rat ventricular myocytes. J Mol Cell Cardiol. 2010 Apr;48(4):773-80. doi: 10.1016/j.yjmcc.2009.10.020. PubMed PMID: 19883656.
14: Silva-Neto MA, Atella GC, Shahabuddin M. Inhibition of Ca2+/calmodulin-dependent protein kinase blocks morphological differentiation of plasmodium gallinaceum zygotes to ookinetes. J Biol Chem. 2002 Apr 19;277(16):14085-91. PubMed PMID: 11827960.
15: Anderson ME, Braun AP, Wu Y, Lu T, Wu Y, Schulman H, Sung RJ. KN-93, an inhibitor of multifunctional Ca++/calmodulin-dependent protein kinase, decreases early afterdepolarizations in rabbit heart. J Pharmacol Exp Ther. 1998 Dec;287(3):996-1006. PubMed PMID: 9864285.
16: Pezhouman A, Singh N, Song Z, Nivala M, Eskandari A, Cao H, Bapat A, Ko CY, Nguyen TP, Qu Z, Karagueuzian HS, Weiss JN. Molecular Basis of Hypokalemia-Induced Ventricular Fibrillation. Circulation. 2015 Oct 20;132(16):1528-37. doi: 10.1161/CIRCULATIONAHA.115.016217. PubMed PMID: 26269574; PubMed Central PMCID: PMC4618042.
17: Rezazadeh S, Claydon TW, Fedida D. KN-93 (2-[N-(2-hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N -methylbenzylamine), a calcium/calmodulin-dependent protein kinase II inhibitor, is a direct extracellular blocker of voltage-gated potassium channels. J Pharmacol Exp Ther. 2006 Apr;317(1):292-9. PubMed PMID: 16368898.
18: Kostic S, Pan B, Guo Y, Yu H, Sapunar D, Kwok WM, Hudmon A, Wu HE, Hogan QH. Regulation of voltage-gated Ca(2+) currents by Ca(2+)/calmodulin-dependent protein kinase II in resting sensory neurons. Mol Cell Neurosci. 2014 Sep;62:10-8. doi: 10.1016/j.mcn.2014.07.004. PubMed PMID: 25064143; PubMed Central PMCID: PMC4187344.
19: Mitsuyama H, Yokoshiki H, Watanabe M, Mizukami K, Shimokawa J, Tsutsui H. Ca2+/calmodulin-dependent protein kinase II increases the susceptibility to the arrhythmogenic action potential alternans in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2014 Jul 15;307(2):H199-206. doi: 10.1152/ajpheart.00387.2012. PubMed PMID: 24858851.
20: Lim NR, Thomas CJ, Silva LS, Yeap YY, Yap S, Bell JR, Delbridge LM, Bogoyevitch MA, Woodman OL, Williams SJ, May CN, Ng DC. Cardioprotective 3',4'-dihydroxyflavonol attenuation of JNK and p38(MAPK) signalling involves CaMKII inhibition. Biochem J. 2013 Dec 1;456(2):149-61. doi: 10.1042/BJ20121538. PubMed PMID: 24032640.